Fig. 7

Estimation of the sensitivity to immunotherapy and chemotherapy among OV patients. (A) The boxplots for the distribution of 8 typical immune checkpoints gene expression (including CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, SIGLEC15, and TIGIT) between the two groups classified by the 6-gene signature. (B) The immunotherapy response prediction of OV patients, refer to the Tumor Immune Dysfunction and Exclusion(TIDE)score. (C) The violin diagrams for the estimated IC50 values distribution for OV patients, in terms of 8 typical chemotherapies, including Bleomycin, Cisplatin, Docetaxel, Gemcitabine, Paclitaxel, Sorafenib, Vinblastine, and Veliparib. The chemotherapy sensitivity analysis was conducted based on the Genomics of Drug Sensitivity in Cancer (GDSC) database. *P-value < 0.05; **P-value < 0.01; ****P-value < 0.0001